N-Power Medicine, Inc.

We're reinventing the 'how' of oncology clinical research. The N-Power Medicine team will be at ASCO 2026 to discuss how prospective external controls and our embedded research model within community standard of care are reshaping evidence generation in oncology. By prospectively collecting trial-compatible data from patients on standard of care, N-Power's ProECA gives sponsors a rigorous, high-quality alternative to randomized control arms, accelerating decision-making in early drug development. Looking forward to connecting with pharma, biotech, and clinical research leaders who are rethinking how oncology trials are designed and run. Connect with our team to learn more about ProECA and our research platform. Mark Lee | Maria Ferrari | Jonathan Daniels | Phil Beck, RPh #ASCO #ClinicalTrials #Oncology #ExternalControlArms #ProECA

We’re excited to be part of the “Where Expedited Pathways, Innovation, Safety, and Patient Access Collide: A KRAS Case Study” session at #AACR26. Our CEO, Mark Lee, MD, PhD, will join leaders across academia, pharma, and policy to discuss one of the most pressing challenges in oncology today. Oncology drug development has made remarkable progress, but as promising therapies emerge, access hasn’t kept pace. Clinical trial capacity is constrained, timelines are long, and trial designs can create barriers to enrollment and execution. To address these challenges, novel approaches, including applications of external control arms, are becoming critical to accelerating development. Platforms like N-Power’s ProECA are part of a broader shift—enabling faster, more efficient evidence generation that brings therapies to patients sooner. We look forward to this important discussion at #AACR26. If you’ll be there, we’d welcome the chance to connect. View session details: https://lnkd.in/ejcx3EYb Liz Jaffee | Timothy Yap | Ignacio Garrido-Laguna, MD, PhD, MBA | Lola Fashoyin-Aje, MD, MPH | Mark Lee | Cristian Massacesi, M.D. | Andrew Rakeman | Mark Wicclair American Association for Cancer Research

Earlier this week, we joined the Friends of Cancer Research public meeting on “Application of External Control Arms in Oncology Drug Development.” As the industry works to accelerate access to promising therapies, there is a critical opportunity to rethink how evidence is generated to support broader adoption of ECAs. This shift calls for more prospective, purpose-built approaches—designed from the outset to produce fit-for-purpose evidence that meets the evolving needs of drug development. Thank you to the panelists for an energizing and forward-looking discussion, underscoring the opportunity and momentum to align expectations, strengthen transparency, and scale the use of ECAs to transform evidence generation in oncology clinical trials. Clay Alspach | Amy Comstock Rick | Joe Franklin | Donna Rivera #ClinicalTrials #Oncology #DrugDevelopment

External Control Arms (ECAs) in Oncology are entering a new phase, moving toward prospective approaches that better inform decision-making across drug development. We are honored to be part of the Friends of Cancer Research's (FOCR) public meeting on “𝗔𝗽𝗽𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝗼𝗳 𝗘𝘅𝘁𝗲𝗿𝗻𝗮𝗹 𝗖𝗼𝗻𝘁𝗿𝗼𝗹 𝗔𝗿𝗺𝘀 𝗶𝗻 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗗𝗿𝘂𝗴 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁." The discussion will focus on methodological insights, real-world implementation, and the evolving policy and regulatory landscape shaping how ECAs are designed, validated, and applied in practice. Our CEO and Co-Founder, Mark Lee, MD, PhD, will join a distinguished panel to discuss new approaches to building ECAs, including prospective and hybrid models, and their expanding role earlier in development to inform phase transitions and enable more efficient trial designs. Looking forward to connecting and continuing this important conversation. April 7, 2026 | 1:10 PM  Session 3 – Policy Perspectives and Regulatory Priorities for ECAs Panelists: Clay Alspach, Leavitt Partners and ACRO (Moderator) Amy Comstock Rick, FDA Joe Franklin, Biotechnology Innovation Organization Mark Lee, N-Power Medicine Donna Rivera, Canal Row Advisors Register for the event here: https://bit.ly/46lTZWy  #ClinicalTrials #Oncology #RWE #ExternalControlArms #DrugDevelopment #ProECA #FriendsECA26  

How can prospectively generated external control arms enable smarter, faster oncology trials? Next week at Medidata NEXT New York 2026, our CEO and Co-Founder, Mark Lee, will join Ruthie Davi, Yiyun (Michael) Zhang, and Bryant F. for a breakout session exploring how prospectively generated ECAs and high-quality historical trial-based external controls can complement randomized designs in oncology. As regulatory thinking and methodological approaches evolve, ECAs are creating new opportunities to advance more efficient oncology trial designs. Breakout Session: Rethinking the Control Arm: Emerging Opportunities for External Control Arms in Oncology Research March 11 | 11:45 AM – 12:15 PM Medidata NEXT, New York #ClinicalTrails #MedidataNext2026 #ProECA #Oncology #OncologyResearch #DrugDevelopment #Next2026

Heading to Precision Medicine World Conference 2026? The N-Power team will be there - Let’s connect! Join us as our CEO, Mark Lee, discusses how Prospective External Control Arms (ProECAs) can reduce reliance on traditional randomized trials by leveraging prospectively generated, trial-compatible data from standard-of-care. March 5 | 11:45–12:00 Showcase Track S1 If you're interested in new approaches to clinical evidence generation and more efficient trial designs, we'd love to meet. PMWC - Precision Medicine World Conference @Tal Behar #PMWC26, #ClinicalTrials #Oncology #ProECA #DrugDevelopment 

We are excited to participate at the PMWC - Precision Medicine World Conference (PMWC) 2026, presenting in the Large-Scale Data Solutions Showcase. Reducing reliance on randomized trials starts with prospectively generated, fit-for-purpose data aligned to active trial designs, incorporating trial-compatible endpoints and prognostic covariates. Our CEO, Mark Lee, will share how N-Power's Prospective External Control Arms (ProECA) are supporting early oncology drug development and  what it takes to enable broader adoption across clinical research. Generation and Application of Prospective External Control Arms (ProECA) March 5 | 11:45–12:00 Showcase Track S1 Attending PMWC? Let's Connect! Tal Behar #PMWC26 #PMWC2026 #PrecisionMedicine #Biotech, #ClinicalTrials #Oncology #ProECA #DrugDevelopment

Today is World Cancer Day.  For all of us at N-Power Medicine, this day- like every day - is a reminder of what's at stake and why our work matters. Patients can't wait and neither can we. We’re committed to accelerating innovation and making research a part of cancer care for more patients than ever before. #Oncology #WorldCancerDay #ClinicalTrials #FiredUp #ReadyToGo

We’re excited to be speaking at SCOPE Summit next week! Our CEO, Mark Lee, will join industry leaders on stage to discuss how data-driven approaches are delivering measurable ROI across clinical development. The panel will bring together different perspectives on how data and technology are reshaping clinical trials, from study designs to trial enrollment and regulatory submissions, including how platforms like N-Power’s Prospective External Control Arms can accelerate clinical development timelines, de-risk phase transition decisions, and expand access to clinical research in community settings. Moderator: Kindra Tatarsky Panelists: Mike Franklin, Jennifer Lum, Zach Taft, MBA If you’re at SCOPE, let’s connect and continue the conversation. Looking forward to the discussion with Kindra Tatarsky, Mike Franklin, Jennifer Lum and Zach Taft, MBA #SCOPE26, #ClinicalTrials #ProECA #Oncology

Wrapping up JPM feeling energized by the conversations and the leaders pushing clinical research forward. It’s encouraging to see growing momentum around innovative approaches to oncology drug development - all with the shared goal of getting therapies to patients faster. We’re excited to turn this momentum into meaningful, real-world impact. 📸 Mark Lee | Michael Seiden MD, PhD | Maria Ferrari | Jonathan Daniels Joel Smith #JPM26 #JPM2026 #ClinicalTrials #Oncology #PrecisionMedicine